Trana Discovery, Inc.

Trana Discovery is a drug discovery technology company that provides a proprietary platform for identifying treatments for bacterial, viral, and fungal infectious diseases. The platform works by screening molecular libraries to identify compounds that bind to the anticodon stem loop (ASL) of organism-specific transfer RNA (tRNA), a mechanism of action that prevents pathogen propagation. By targeting these unique, highly conserved regions of tRNA, the technology aims to develop highly selective anti-infective agents that kill specific pathogens while minimizing disruption to normal host flora and avoiding traditional resistance issues.

The company was spun out of North Carolina State University in 2005 to commercialize its tRNA-based discovery platform. It addresses the global challenge of antimicrobial resistance by providing targeted, narrow-spectrum solutions for human and agricultural applications. Trana Discovery operates with an executive management team of industry veterans and utilizes a deferred compensation model with independent agents, focusing its research efforts on developing effective therapeutics for infectious diseases where current treatment options are limited or ineffective.